Deal overview
| Target | NUVALENT INC |
|---|---|
| Bidder | GSK PLC |
| Price | £80.00 Full version or £25.00 Light version |
| Publication Date | Jun 09, 2026 |
| Abstract | On 9 June 2026, the quoted UK-based pharmaceutical group GSK plc ("GSK") announced a cash offer for the Boston-based clinical-stage oncology company Nuvalent, Inc. ("Nuvalent"). GSK would pay US$ 124 per Nuvalent share in cash, which implied an equity value of approximately US$ 10.6 billion for 100% of the company's share capital. The transaction was expected to close in Q3 ... |
| Number of pages (Full version) | 8 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2026 M&A Monitor Limited
